You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Long-term cognitive outcome of Alzheimer’s disease and dementia with Lewy bodies: dual disease is worse
|
|---|---|
| Published in |
Alzheimer's Research & Therapy, June 2017
|
| DOI | 10.1186/s13195-017-0272-8 |
| Pubmed ID | |
| Authors |
Frédéric Blanc, Rachid Mahmoudi, Thérèse Jonveaux, Jean Galmiche, Gilles Chopard, Benjamin Cretin, Catherine Demuynck, Catherine Martin-Hunyadi, Nathalie Philippi, François Sellal, Jean-Marc Michel, Gregory Tio, Melanie Stackfleth, Pierre Vandel, Eloi Magnin, Jean-Luc Novella, Georges Kaltenbach, Athanase Benetos, Erik A. Sauleau |
| Abstract |
Longitudinal studies of dementia with Lewy bodies (DLB) are rare. Clinically, DLB is usually considered to worsen into Alzheimer's disease (AD). The aim of our study was to compare the rate of the cognitive decline in DLB, AD, and the association of the two diseases (AD + DLB). Using the Regional Network for Diagnostic Aid and Management of Patients with Cognitive Impairment database, which includes all the patients seen at all memory clinics (medical consultation and day hospitals) in four French regions, and beta regression, we compared the longitudinal the Mini-Mental State Examination scores of 1159 patients with AD (n = 1000), DLB (n = 131) and AD + DLB (association of the two) (n = 28) during follow-up of at least 4 years. The mean follow-up of the patients was 5.88 years. Using beta regression without propensity scores, the comparison of the decline of patients with AD and patients with DLB did not show a significant difference, but the decline of patients with AD + DLB was worse than that of either patients with DLB (P = 0.006) or patients with AD (P < 0.001). Using beta regression weighted by a propensity score, comparison of patients with AD and patients with DLB showed a faster decline for patients with DLB (P < 0.001). The comparison of the decline of patients with AD + DLB with that of patients with DLB (P < 0.001) and patients with AD (P < 0.001) showed that the decline was clearly worse in the patients with dual disease. Whatever the analysis, the rate of decline is faster in patients with AD + DLB dual disease. The identification of such patients is important to enable clinicians to optimise treatment and care and to better inform and help patients and caregivers. |
X Demographics
The data shown below were collected from the profiles of 19 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 6 | 32% |
| France | 3 | 16% |
| Netherlands | 2 | 11% |
| Mauritius | 1 | 5% |
| Italy | 1 | 5% |
| Unknown | 6 | 32% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 68% |
| Practitioners (doctors, other healthcare professionals) | 3 | 16% |
| Scientists | 2 | 11% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 64 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 16% |
| Student > Ph. D. Student | 7 | 11% |
| Student > Bachelor | 6 | 9% |
| Student > Doctoral Student | 4 | 6% |
| Researcher | 4 | 6% |
| Other | 6 | 9% |
| Unknown | 27 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 17% |
| Nursing and Health Professions | 4 | 6% |
| Psychology | 4 | 6% |
| Neuroscience | 4 | 6% |
| Computer Science | 2 | 3% |
| Other | 9 | 14% |
| Unknown | 30 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 July 2023.
All research outputs
#2,753,576
of 24,880,704 outputs
Outputs from Alzheimer's Research & Therapy
#660
of 1,410 outputs
Outputs of similar age
#50,177
of 321,058 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#12
of 26 outputs
Altmetric has tracked 24,880,704 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,410 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.6. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 321,058 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.